Sign up to save your podcasts
Or
Share Experts Talk CLL #1 : Current Treatment Options in CLL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #1 : Current Treatment Options in CLL
A discussion between Dr. Peter Anglin and Dr. Anthony Mato (Fall 2021)
In this episode, Dr. Peter Anglin and Dr. Anthony Mato discuss therapeutic decision-making in the evolving CLL treatment landscape and the diminishing role of chemoimmunotherapy. They provide their take on selecting between continuous therapy with BTK inhibitors and finite treatment duration with venetoclax-based regimens and they elaborate on various factors that come into play when choosing first and subsequent line therapy.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Anthony R. Mato, MD, MSCE Associate Member, Memorial Sloan Kettering Cancer Director, Chronic Lymphocytic Leukemia (CLL) Program at MSKCC New York, USA
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Anthony Mato (Fall 2021)
In this episode, Dr. Peter Anglin and Dr. Anthony Mato discuss therapeutic decision-making in the evolving CLL treatment landscape and the diminishing role of chemoimmunotherapy. They provide their take on selecting between continuous therapy with BTK inhibitors and finite treatment duration with venetoclax-based regimens and they elaborate on various factors that come into play when choosing first and subsequent line therapy.
Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON
Anthony R. Mato, MD, MSCE Associate Member, Memorial Sloan Kettering Cancer Director, Chronic Lymphocytic Leukemia (CLL) Program at MSKCC New York, USA
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.